https://www.prothena.com/
Prothena Biosciences - expertise in protein dysregulation
Aug 28, 2025 - Discover the impact of more than 3 decades of expertise in the biology of misfolded proteins. View our science, pipeline, clinical trial info, and more
prothenabiosciencesexpertiseproteindysregulation
https://www.businesswire.com/news/home/20230110005686/en/Cerveau-Technologies-Inc.-and-Prothena-Sign-Agreement-to-Provide-Novel-Tau-Imaging-Biomarker-for-Research-and-Development-of-Investigational-Therapeutics-for-Neurodegenerative-Diseases
Cerveau Technologies Inc. and Prothena Sign Agreement to Provide Novel Tau Imaging Biomarker for...
Cerveau Technologies, Inc. today announced a research collaboration agreement with Othair Prothena Limited, a subsidiary of Prothena Corporation plc (Prothen...
https://www.nasdaq.com/market-activity/stocks/prta
Prothena Corporation plc Ordinary Shares (PRTA) Stock Price, Quote, News & History | Nasdaq
Discover real-time Prothena Corporation plc Ordinary Shares (PRTA) stock prices, quotes, historical data, news, and Insights for informed trading and...
ordinary shares
https://investingnews.com/daily/life-science-investing/biotech-investing/prothena-reports-first-quarter-2018-financial-results-provides-rd-update/
Prothena Reports First Quarter 2018 Financial Results and Provides R&D Update | INN
Jan 4, 2026 - Prothena (NASDAQ:PRTA), a clinical-stage biotechnology company focused on the discovery and development of novel therapies in the neuroscience and orphan...
https://www.macrotrends.net/stocks/charts/PRTA/prothena/net-income
Prothena Net Income 2012-2026 | PRTA | MacroTrends
Prothena net income from 2012 to 2026. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been...
net incomeprothena20122026prta
https://investingnews.com/prothena-announces-leadership-team-updates/
Prothena Announces Leadership Team Updates | INN
Apr 10, 2026 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein...
leadership teamprothenaannouncesupdatesinn
https://finviz.com/quote?t=PRTA&ty=oc&ta=0&p=d
PRTA - Prothena Corp Plc Options
PRTA - Prothena Corp Plc - Stock screener for investors and traders, financial visualizations.
prtaprothenacorpplcoptions
https://www.biospace.com/prothena-announces-presentation-of-clinical-data-from-the-ongoing-phase-i-ii-neod001-study-and-systemic-amyloidosis-patient-survey-results-at-20th-con
Prothena Announces Presentation Of Clinical Data From The Ongoing Phase I/II NEOD001 Study And...
https://investingnews.com/stocks/nasdaq-prta/prothena-corporation-plc/
Prothena Corporation plc Stock Price, News, Quote & History | INN
Sep 11, 2025 - Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change...
stock pricequote historyprothenacorporationplc
https://www.businesswire.com/news/home/20260427325583/en/Prothena-Announces-Novo-Nordisk-Obtains-Fast-Track-Designation-from-the-U.S.-FDA-for-Coramitug-PRX004-in-ATTR-Amyloidosis-with-Cardiomyopathy
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug...
Prothena announces Novo Nordisk obtains Fast Track Designation from the U.S. FDA for coramitug (PRX004) in ATTR amyloidosis with cardiomyopathy
https://www.businesswire.com/news/home/20250827764180/en/Prothena-Provides-Update-on-PRX012-and-Announces-Results-from-the-Phase-1-ASCENT-Clinical-Program
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program
https://www.fiercebiotech.com/biotech/prothena-celgene-ink-neuro-r-d-pact-potentially-worth-2b
Prothena, Celgene ink neuro R&D pact potentially worth $2B+ | Fierce Biotech
Mar 20, 2018 - Celgene has been making deals left and right lately, kicking off the year
r d
https://www.fiercebiotech.com/research/prothena-says-preclinical-alzheimer-s-drug-candidate-binds-about-11-times-more-than
Prothena rolls out preclinical data for anti-amyloid Alzheimer's candidate to rival Biogen's...
Jul 26, 2021 - The build up of amyloid-beta in the brain has been a prime target of Alzheimer's drug developers, including Biogen with its controversial new drug Aduhelm,...
https://www.sofi.com/invest/stock/PRTA/
Buy Prothena Corporation Stock - PRTA Stock Price, Quote & News | SoFi
See real time price charts for PRTA stock, historical data, and recent news. Buy PRTA stock online with no commission fees.
price quotebuyprothenacorporationstock
https://www.prnewswire.com/news-releases/prothena-shareholder-alert---prta-stock-drops-almost-70---kehoe-law-firm-pc-investigating-300635318.html
Prothena Shareholder Alert - PRTA Stock Drops Almost 70% - Kehoe Law Firm, P.C. Investigating
/PRNewswire/ -- Kehoe Law Firm, P.C. is conducting a securities investigation on behalf of investors of Prothena Corporation plc (NASDAQ: PRTA) to determine...
https://finviz.com/news/328485/wall-street-analysts-believe-prothena-prta-could-rally-11809-heres-is-how-to-trade
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade
Stock screener for investors and traders, financial visualizations.
https://www.benzinga.com/news/earnings/23/02/31011283/earnings-outlook-for-prothena-corp
Earnings Outlook For Prothena Corp - Prothena Corp (NASDAQ:PRTA) - Benzinga
earningsoutlookprothenacorpnasdaq
https://finviz.com/quote?t=PRTA&ty=ea&ta=1&p=d
PRTA - Prothena Corp Plc Earnings
PRTA - Prothena Corp Plc - Stock screener for investors and traders, financial visualizations.
prtaprothenacorpplcearnings
https://www.jdsupra.com/legalnews/prothena-corporation-plc-confirms-6912228/
Prothena Corporation, PLC Confirms Recent Data Breach Following Compromised Employee Email Account...
Recently, Prothena Corporation, PLC confirmed that certain sensitive consumer information was exposed after an unauthorized party gained access to an...
recent data
https://finviz.com/quote?t=PRTA&ta=1&p=d&ty=fc
PRTA - Prothena Corp Plc Forecast, Target Price
PRTA - Prothena Corp Plc - Stock screener for investors and traders, financial visualizations.
prtaprothenacorpplcforecast
https://www.prnewswire.com/news-releases/scottscott-attorneys-at-law-llp-reminds-investors-of-securities-class-action-against-prothena-corporation-plc-prta-300668887.html
Scott+Scott Attorneys at Law LLP Reminds Investors of Securities Class Action Against Prothena...
/PRNewswire/ -- Scott+Scott Attorneys at Law LLP ("Scott+Scott"), a national securities and consumer rights litigation firm, reminds investors that a class...
attorneys at law
https://finviz.com/quote?t=PRTA
PRTA - Prothena Corp Plc Stock Price and Quote
PRTA - Prothena Corp Plc - Stock screener for investors and traders, financial visualizations.
stock priceprtaprothenacorpplc
https://www.biospace.com/prothena-announces-bristol-myers-squibb-opt-in-for-worldwide-rights-of-prx005-a-novel-anti-mtbr-tau-antibody
Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel...
Jul 11, 2023 - Prothena Corporation plc announced that Bristol Myers Squibb exercised its option under the global neuroscience research and development collaboration to...
https://finviz.com/news/316621/prothena-prta-reports-q4-loss-lags-revenue-estimates
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
Stock screener for investors and traders, financial visualizations.
prothenaprtareportsq4loss
https://www.benzinga.com/news/21/06/21430508/return-on-capital-employed-overview-prothena-corp
Return On Capital Employed Overview: Prothena Corp - Prothena Corp (NASDAQ:PRTA) - Benzinga
Jun 4, 2021 - In Q1, Prothena Corp (NASDAQ:PRTA) posted sales of $160.00 thousand. Earnings were up 5.94%, but Prothena Corp still reported an overall loss of $32.11...
return on capital employedoverviewprothenacorpnasdaq